Accéder au contenu
Merck

A reverse genetic screen in Drosophila using a deletion-inducing mutagen.

Genome biology (2004-10-06)
Knud Nairz, Peder Zipperlen, Charles Dearolf, Konrad Basler, Ernst Hafen
RÉSUMÉ

We report the use of the cross-linking drug hexamethylphosphoramide (HMPA), which introduces small deletions, as a mutagen suitable for reverse genetics in the model organism Drosophila melanogaster. A compatible mutation-detection method based on resolution of PCR fragment-length polymorphisms on standard DNA sequencers is implemented. As the spectrum of HMPA-induced mutations is similar in a variety of organisms, it should be possible to transfer this mutagenesis and detection procedure to other model systems.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Hexamethylphosphoramide, 99%
Sigma-Aldrich
Hexamethylphosphoramide, absolute, over molecular sieve (H2O ≤0.03%), ≥98.0% (GC)
Sigma-Aldrich
Hexamethylphosphoramide, purum, ≥98.0% (GC)